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Purpose. In Italy we say that the most unlucky things can happen to physicians when they get sick, despite the attention of
colleagues. To conﬁrm this rumor, we report the sad story of a surgeon with bilateral vitreitis and glaucoma unresponsive
to traditional therapies. Methods/Design.C a s er e p o r t .Results. After one year of steroidal and immunosuppressive therapy, a
vitrectomy, and a trabeculectomy for unresponsive bilateral vitreitis and glaucoma, MRI showed a multicentre primary central
nervous system lymphoma, which was the underlying cause of the masquerade syndrome. Conclusions. All ophthalmologists and
clinicians must be aware of masquerade syndromes, in order to avoid delays in diagnosis.
1.Introduction
In Italy we often say that doctors may be especially unlucky
when they get sick, and that the strangest things can happen
to them, despite the attention of colleagues. To conﬁrm this
rumor, we recount the sad story of an unfortunate colleague
who suﬀered many tribulations and waited a year for a grim
but not diﬃcult diagnosis.
2.CaseReport
In December 2009, a 44-year-old surgeon underwent bilat-
eral phacoemulsiﬁcation and IOL implantation for surgical
correctionofa10-dioptermyopiainaprivateclinicinnorth-
ern Italy. Her natural visual acuity after surgery was 20/20 in
both eyes.
Three months after surgery, she referred blurred vision
in both eyes. A diagnosis of bilateral vitreous hemorrhage
was made and she was referred for ultrasonography, which
showed severe vitreitis, with intense ﬂare cells and dense
membranes (Figures 1(c) and 1(d)). At this time, her visual
acuity had dropped to 20/200 in both eyes. At slit lamp
examination, a mild inﬂammation of the anterior segment
was present, the IOL was well positioned in the capsular bag,
and dense vitreitis veiled the fundus. Intraocular pressure
was 18mmHg in both eyes.
She returned to her ophthalmologist and underwent
repeated cycles of topical, subconjunctival and subtenon
injections of steroids (Betamethasone phosphate), as well as
mydriatic and cyclopegic eye drops. To rule out other poten-
tial causes of uveitis, a comprehensive workup was per-
formed, but all tests were unremarkable.
After three months of steroid therapy, the lack of im-
provement led the ophthalmologist to prescribe systemic
steroid therapy (Prednisone 1gr/Kg/day) but the patient
gained no beneﬁt even from this therapy. At this time, her
visual acuity had dropped to light perception in both eyes,
and the IOP had reached 35mmHg in the right eye and
50mmHginthelefteye.Antiglaucomatoustherapywasthen
prescribed (topical Beta blockers and topical and systemic
carbonic anhydrase inhibitors) and, on the suspicion of
a steroid-induced glaucoma, systemic steroid therapy was2 Case Reports in Ophthalmological Medicine
(a) (b)
(c) (d)
(e)
Figure 1: (a) Right eye showing a hazy vitreous humor. (b) Left eye showing an intense inﬂammation of the anterior chamber, with corneal
precipitates. (c) Echographic examination of the vitreous in the right eye. (d) UBM examination of the ciliary body showing vitreous
membranes adherent to the pars plana. (e) MR image showing a hypointense multifocal lesion occupying much of the right frontal and
temporal lobe, the right occipital lobe, and the left parietal lobe.
stopped and the patient was referred to an immunologist.
She was then prescribed Cyclosporine A at the dosage of
3mg/Kg/die; but despite this therapy her sight did not
improve, the IOP did not decrease, and she developed hyper-
tension and renal failure.
This unfortunate doctor then went to a new ophthal-
mologist, who performed a pars plana vitrectomy and a
trabeculectomy in her left eye; but, despite a clear vitreous
chamber, her left eye visual acuity did not improve because
a dense inﬂammatory reaction developed in the anterior
chamber (Figure 1(b)), while the IOP decreased for a few
days then returned to 50mmHg despite therapy.
She consulted a new immunologist, who changed
the immunosuppressive therapy, prescribing prednisone
1mg/Kg/day and MTX 20mg/week. It was at this time
(December 2010) that the patient came to our attention.
Her visual acuity was light perception in both eyes, the
IOP was 35mmHg RE and 50mmHg LE, despite topical
and systemic antiglaucomatous therapy. In the RE a dense
vitreitis hindered fundus examination (Figure 1(a)), andCase Reports in Ophthalmological Medicine 3
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Figure 2: (a) Areas of necrosis associated to perivascular islands of viable lymphoma cells (hematoxylin and eosin; original magniﬁcation
×200), (b) Characteristic perivascular accumulation and spread of blastic lymphoma cells (hematoxylin and eosin; original magniﬁcation
×100).(c)PCNSLcellsdisplayconsistentCD20immunoreactivity(originalmagniﬁcation ×100).(d)PCNSLcellsdisplayconsistentMUM-
1 immunoreactivity (original magniﬁcation ×100).
a pale optic nerve was scarcely visible at the fundus examina-
tion of the LE. An intense granulomatous inﬂammation was
present in the anterior chamber of the left eye (Figure 1(b)).
At this time, the patient began to show personality changes:
shebecameoblivioustotheenvironmentanddidnotseemto
attribute any importance to the severity of her visual defect.
Despite the new systemic immunosuppressive therapy, no
improvement was obtained.
Suddenly, one day, the patient fainted. She was imme-
diately taken to the ER, where she underwent MRI
(Figure 1(e)). MRI of the brain showed a hypointense
multifocal lesion occupying much of the right frontal and
temporal lobe, the right occipital lobe, and the left parietal
lobe.InT1-weightedMRIimages,thelesionwashypointense
while at T2-weighted images, it was hyperintense with
contrast enhancement. The lesions showed cystic foci after
gadolinium injection, with a ring-like enhancement rep-
resenting central necrosis. Intense peritumoral edema was
present.
A diagnosis of PCNSL was suspected and a stereotactic
biopsy was performed.
3.Pathological Findings
Histological examination of the specimen showed neoplas-
tic blastic cells arranged in dense cellular aggregates with
prevalent diﬀuse growth pattern and with large pleomorphic
nuclei and distinct nucleoli (Figure 2(a)). Several areas of
coagulative necrosis were observed in the middle of perivas-
cular islands of viable tumor cells. Typical angiocentric inﬁl-
tration pattern was noted (Figure 2(b)). The proliferation
indexwasveryprominent.Thecellsdemonstratedconsistent
immunoreactivity for CD20 and MUM-1 (Figure 2(c)). No
immunoreactivityforCD3,CD138,andGlialﬁbrillaryacidic
protein (GFAP) was detected in the cells (Figure 2(d)). A
diagnosis of primary CNS diﬀuse large B-cell lymphoma was
made.
The patient then underwent chemo- and radio-therapy:
First-line therapy was based on systemic chemotherapy with
high-dose methotrexate (5g/m2) in combination with Ara-
C (cytarabine) (2g/m2) twice daily for two cycles, followed
by whole brain radiation therapy (WBRT) with a dosage of
24–36 Gy.
The intraocular inﬂammation resolved. Her best cor-
rected visual acuity is now 60/200 in the RE and 20/200
in the LE. At fundus examination, a bilateral optic glau-
comatous subatrophy is present, and the vitreous ﬂoaters
havecompletelydisappeared.TheIOPdecreasedinbotheyes
to 16mmHg without any therapy, probably because it was
secondary to blockage of the trabecular meshwork by the
lymphoma cells in the anterior chamber.4 Case Reports in Ophthalmological Medicine
4. Discussion
The term “Masquerade syndrome” is used for malignant
diseases manifesting as peri- or intraocular inﬂammations of
unknown origin (iritis, vitritis, uveitis) [1].
One of the following diagnoses must be suspected in
all cases of ocular inﬂammation unresponsive to classi-
cal therapy: primary central nervous system lymphoma
(PCNSL), primary intraocular lymphoma (PIOL), choroid
melanoma, retinoblastoma, intraocular metastases, para-
neoplastic retinopathy [2]. Patients complain of increasingly
blurred vision. This is either due to inﬂammation of the
anterior chamber (iritis), or, more commonly, to an inﬁl-
tration of the vitreous body (vitritis, uveitis), the retina,
and the choroid. Patients may also complain of so-called
“ﬂoaters.” A reduction in visual acuity and even amaurosis
can occur. These changes may be limited to just one eye.
Primary central nervous system lymphoma, on the other
hand, causes bilateral involvement in 80% of cases [3, 4].
A prompt diagnosis is very important. A potential delay
in reaching a diagnosis arises as a masquerade syndrome
frequentlyresponds tocorticosteroidswhichmaskthesymp-
toms.
Making the right diagnosis has vital consequences for
patients as most cases are malignant. PCNSL, in particular,
should be considered in the diﬀerential diagnosis in middle-
aged patients as it is the commonest cause of a masquerade
syndrome. In order to diﬀerentiate between other causes
of masquerade syndrome, in addition to a careful history
and clinical examination, the following investigations are
essential: ultrasound [5], ﬂuorescent angiography, neu-
roimaging [6], CSF cytology and ﬁnally a vitrectomy [7], or
chorioretinal biopsy with immunohistological examination
[8].
Our patient was particularly unlucky: despite the signs
that might suggest a masquerade syndrome, no physi-
cian suspected the underlying disease, nor were immuno-
histological and immunohistochemical examinations of the
specimen performed at the time of the vitrectomy.
Furthermore, the prolonged steroid therapy certainly
contributedtohidetheunderlyingdisease,andtheimmuno-
suppressive therapy probably facilitated the multicentric
manifestation of the lymphoma, as in immunocompromised
patients.
All ophthalmologists and clinicians must be aware of
masquerade syndromes, in order to avoid a delay in diagno-
sis, as occurred in this case of our unlucky colleague.
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